Sun Pharmaceutical Industries Limited — PPTs, 04-03-2025: Investor Presentation

**Financial Highlights:** Sun Pharmaceutical Industries reported FY24 sales of ₹47,758 crore, marking a 10% growth from FY23. The company’s gross profit reached ₹37,096 crore with a gross margin of 77.7%. Notably, EBITDA was recorded at ₹13,023 crore, reflecting a 12% margin, while net profit increased by 13% year-on-year to ₹9,576 crore. The strong performance was underpinned by robust growth in core therapeutic areas.

**Strategic Initiatives and Growth Drivers:** The company is strategically enhancing its specialty and complex product portfolio, with over 32% of FY24 revenues stemming from specialty sales. Sun Pharma aims to increase its share in high-entry barrier segments, leveraging R&D investments that represent 6.7% of sales.

**Business Developments:** Key acquisitions such as Concert Pharmaceuticals significantly bolster the dermatology division. Sun Pharma continues to focus on global specialty growth, launching new products in the US market that capture significant market segments.

**Market Position and Competitive Advantage:** Sun Pharma remains the largest pharma company in India, holding an 8.2% market share and ranking first in multiple prescription categories. With a pipeline of 650 ANDAs, it is positioned as the 12th largest player in the US generics market.

**Investor Implications:** With a strong balance sheet and aggressive growth strategy in both domestic and international markets, Sun Pharma presents a positive outlook for investors, driven by its expanding specialty product offerings and commitment to R&D innovation.